




ASCEPT-MPGPCR

JOINT SCIENTIFIC MEETING **27-30 NOVEMBER 2016**

MELBOURNE CONVENTION & EXHIBITION CENTRE

Therapeutic targeting: right place, right time, right effect

www.ascept-mpgpcr2016.com



Download the
meeting app



Meeting Program

Sunday 27 November 2016

09:30 – 19:30	Registration desk open Clarendon Auditorium Foyer, Melbourne Convention and Exhibition Centre		
10:00 – 12:00	ASCEPT Board meeting Room: Trust Room	Pharmacogenomics workshop Room: Clarendon Room D Chair: Prof Andrew Somogyi Characterisation of signalling and regulation of common calcitonin receptor splice variants and polymorphisms Ms Emma Dal Maso A new collaboration between pharmacists and doctors through delivering a clinical pharmacogenomics testing service in Australia Mr Sam Mostafa Commercial pharmacogenetic-based decision-support tools in psychiatry Dr Chad Bousman AGRF services to support pharmacogenomics research Mr Matthew Tinning Pharmacogenomics SIG AGM	
12:30 – 15:00	Education forum Room: Clarendon Room C Chair: Dr Lynette Fernandes	Clinical Pharmacology workshop: Misconceptions no longer lost in translation Room: Clarendon Room D Chair: Assoc Prof Darren Roberts	Careers workshop Room: Clarendon Auditorium Chairs: Mr Alex Gillis and Mr Bala Umashankar
	12:30 – 13:30 Pharmacogenomics Dr Janet Collier, University of Adelaide	Reality bites from bench to bedside – the latest scoop on snake bite and anti-venom research Dr Anjana Silva, Monash University and Dr Christopher Johnston, University of Newcastle	Paths to teaching-focused positions in academia Dr Tina Hinton, The University of Sydney
	13:30 – 14:30 Concept inventory, learning outcomes and MCQs	Safe as Houses? Paracetamol poisoning and treatment Prof Nicholas Buckley, The University of Sydney and Dr Xin Liu, The University of Queensland Translational Research Institute	Starting your own business in medical sciences Prof Steven Charlton, University of Nottingham, UK
	14:30 – 15:00 Education Forum AGM	Uses, misuses and abuses – policy and public health perspectives on alcohol and medicines misuse Dr Rose Cairns and Dr Kate Chitty, The University of Sydney	Switching fields to pursue the career that inspires you Dr Wendy Imlach, The University of Sydney Drug discovery research in the world of pharma Dr Chris Langmead, Monash University Getting started in the pharmaceutical industry Mrs Brenda Pote, Roche Careers in clinical pharmacology Prof Sarah Hillmer, Royal North Shore Hospital
15:00 – 15:25	Comfort break		
15:30 – 16:30	Conference opening and acknowledgement of country Room: Clarendon Auditorium Prof Dom Geraghty, ASCEPT President		
	Keynote address Chair: Prof Arthur Christopoulos Allosteric mechanisms of receptor function and modulation: Towards a new pharmacology Prof Jean-Pierre Changeux, Pasteur Institute, Paris, France - 100		
	Sponsored by  		
16:30 – 16:35	Comfort break		
16:35 – 18:35	ASCEPT Denis Wade New Investigators symposium Room: Clarendon Auditorium Chair: Prof Dom Geraghty		
	16:35 – 17:05	Exploring Class B GPCR signalling in sensory neurons - 101 Dr Christopher Walker, University of Auckland, New Zealand	
17:05 – 17:35	Plasma membrane calcium channels in the regulation of hypoxia events in breast cancer cells - 102 Dr Iman Azimi, The University of Queensland		
17:35 – 18:05	Integrating quantitative clinical pharmacology to expedite pediatric drug development - 103 Dr Kashyap Patel, Monash University; d3 Medicine Ltd		
18:05 – 18:35	Using animal models to identify novel targets in respiratory disease - 104 Dr Chantal Donovan, Hunter Medical Research Institute; University of Newcastle		
18:35 – 19:30	Welcome reception Clarendon Auditorium Foyer, Melbourne Convention and Exhibition Centre		

Social Media

Please use the hashtag #ASCEPT_MPGPCR to communicate about the conference, network and share ideas. Follow the ASCEPT-MPGPCR conference @ASCEPTanz and @DDB_MPGPCR.

In today's world it is important to understand, as we are sure you all do, information on social media is readily available for the world to see and potentially be interpreted out of the context it was given in. We recommend that you avoid posting anything online that you would not be happy for your employer or professional body to view. If you have your own individual presence on social media it is a good idea to have a disclaimer on your profile eg: 'All views expressed on this site are my own and do not necessarily reflect those of my employer or professional body'.

Due to the sensitive nature of data and preliminary, unpublished research findings, filming, photography and recording of presentations and poster sessions is prohibited without prior consent.

Monday 28 November 2016

07:30 – 18:00	Registration desk open			
	Clarendon Auditorium Foyer, Melbourne Convention and Exhibition Centre			
08:30 – 09:30	British Pharmacological Society keynote address			
	Room: Clarendon Auditorium			
	Chair: Dr David Webb			
	Pharmacology and functions of the long chain fatty acid receptors FFA1/GPR40 and FFA4/GPR120 Prof Graeme Milligan, University of Glasgow, UK - 200			
09:30 – 10:25	Morning tea with exhibitors			Sponsored by
	Clarendon Auditorium Foyer			
	ASCEPT poster presentations: Cardiovascular; Clinical Pharmacology; Drug Discovery; Drug Disposition and Response			
10:30 – 12:30	Symposium 1: Airway inflammation and remodeling	Symposium 2: Therapeutic targeting of exposure and effect in oncology	Symposium 3: Calcium permeable ion channels: links to GPCRs, drug toxicity pathways and disease	Symposium 4: ISN Symposium on translational neuroscience of GPCRs
	Sponsored by  THE UNIVERSITY OF MELBOURNE		Sponsored by 	Sponsored by 
	Room: Clarendon Room D	Room: Clarendon Room A	Room: Clarendon Room B	Room: Clarendon Auditorium
	Chair: Prof Alistair Stewart	Chairs: Dr Andrew Rowland and Dr David Foster	Chair: Prof Greg Monteith	Chair: Dr Karen Gregory
10:30 – 11:00	Airway epithelial steroid insensitivity - 201 Dr Christine Keenan, The University of Melbourne	Complexities of CYP mediated kinase inhibitors metabolism and interactions - 205 Prof Gerd Mikus, University Hospital, Heidelberg, Germany	Astrocytic calcium signalling in health and disease - 209 Prof Masamitsu Iino, The University of Tokyo, Japan	Positive allosteric modulators of muscarinic acetylcholine receptors for treatment of CNS disorders - 213 Prof P. Jeffrey Conn, Vanderbilt Medical Center, USA
11:00 – 11:30	Mast cells at the centre - 202 Dr Graham Mackay, The University of Melbourne	Genetics of imatinib disposition - 206 Dr Daniel Barratt, University of Adelaide	Physiologically relevant opening of TRPV4 by signalling from G protein-coupled receptors - 210 Prof Peter McIntyre, RMIT University	Dopamine in schizophrenia: Where does it stand in the cascade of pathological events? - 214 Prof Anissa Abi-Dargham, Stony Brook University, USA
11:30 – 12:00	Targeting oxidant-dependent mechanisms for the treatment of COPD and its co-morbidities - 203 Assoc Prof Ross Vlahos, RMIT University; The University of Melbourne	Predictors of therapeutic and adverse outcomes with targeted anticancer drugs - 207 Assoc Prof Michael Soric, Flinders University	TRPM2 channels as mediators of oxidative stress-induced liver damage - 211 Assoc Prof Grigori Rychkov, The University of Adelaide; South Australian Health and Medical Research Institute	mGluR5 and its potential role in ASD - 215 Prof Stan Skafidas, The University of Melbourne
12:00 – 12:30	RGS protein dysfunction in Asthma - 204 Prof Reynold Panettieri, Rutgers University, USA	Bayesian forecasting to predict drug exposure - 208 Assoc Prof Richard Upton, University of South Australia	TRPC1 in the regulation of pathways involved in breast cancer metastasis - 212 Dr Iman Azimi, The University of Queensland Translational Research Institute	M1-muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss - 216 Dr Sophie Bradley, University of Glasgow, UK Extrapyramidal side effects of antipsychotic drugs are linked to their association kinetics at the dopamine D2 receptor - 217 Prof Steven Charlton, University of Nottingham, UK
12:30 – 13:25	Lunch with exhibitors			SIG meeting: Inflammation/Respiratory
	Clarendon Auditorium Foyer			Room: Clarendon Room E
	ASCEPT poster presentations: Cardiovascular; Clinical Pharmacology; Drug Discovery; Drug Disposition and Response			SIG meeting: Toxicology
				Room: Clarendon Room B

Meeting attendees must gain approval from a speaker or poster presenter prior to quoting or publishing that individual's scientific results. This policy includes any use of social media or information sharing related to the conference. We respectfully ask that if you attend a presentation where a speaker has communicated that they do not wish to have their presentation commented on in the social media environment that you adhere to this request. If you are presenting preliminary data, etc. and do not wish the results to be broadcast, please use the following logo with your presentation ask the audience not to refrain from posting your material. It should appear on the title slide or poster, as well as all the slides you do not want posted, so that your audience recognizes your request.

"I request that my presentation is not commented or posted about on social media"

Thank you.



13:30 – 15:30	Oral presentations 1: Inflammation/Respiratory and Neuro- and Behavioural Pharmacology	Oral presentations 2: ASCEPT Garth McQueen Oral Prize	Oral presentations 3: Drug Discovery	Oral presentations 4: Clinical Pharmacology and Drug Disposition and Response
	Room: Clarendon Room D	Room: Clarendon Room A	Room: Clarendon Room B	Room: Clarendon Auditorium
	Chairs: Dr Stavros Selemidis and Dr Nicole Jones	Chair: Dr Tina Hinton	Chairs: Dr Laura Kilpatrick and Assoc Prof Kevin Pflieger	Chair: Assoc Prof Darren Roberts
13:30 – 13:45	The use of three-dimensional cell culture models in the study of idiopathic pulmonary fibrosis - 218 Mr Asres Mitke, The University of Melbourne	Cortisol inhibits selected actions of inhaled corticosteroids (ICS) in human airway epithelium - 226 Miss Danica Radojicic, The University of Melbourne	The potential role of a novel endogenous allosteric modulator of muscarinic acetylcholine receptors - 234 Ms Ee Von Moo, Monash University	Metabolism of the Australian medicinal plant compound polyandric acid A: In silico and in vitro approaches - 242 Mr Matthew Bendikov, University of South Australia
13:45 – 14:00	HTR2A mediates 5-HT-induced oedema in the mouse trachea, oesophagus and bladder - 219 Ms Larissa Dill, RMIT University	Assessment of cytosolic free calcium levels in MDA-MB-231 breast cancer cells undergoing cell death following treatment with ceramide and staurosporine - 227 Mr John Bassett, The University of Queensland	Tacrine is a novel allosteric modulator of the β_2-adrenoceptor - 235 Mr Brendan Wilkins, University of New South Wales	Preclinical model to identify adverse geriatric outcomes from polypharmacy and Drug Burden Index - 243 Dr John Mach, Kolling Institute; The University of Sydney; Royal North Shore Hospital
14:00 – 14:15	FGD2: A new modulator of mast cell activation - 220 Mr Jeremy Metha, The University of Melbourne	CCL18 and reactive oxygen species are potential mediators of the pro-fibrotic actions of M2 macrophages - 228 Ms Caitlin Lewis, Monash University	Functional analysis of novel allosteric modulators at the M1 muscarinic acetylcholine receptor - 236 Dr Emma Van Der Westhuizen, Monash University	Therapeutic Drug Monitoring (TDM) of Vancomycin - 244 Miss Crystal Li, University of New South Wales
14:15 – 14:30	Respiratory syncytial virus-induced glucocorticoid insensitivity in bronchial epithelial cells: Role of pathogen-associated molecular patterns (PAMPs) - 221 Ms Asmaa Radwan, University of Melbourne	Pannexin-1 channels and P2X7 receptors in a human colonic mucosa model of colitis: Potential roles in inflammatory bowel disease - 229 Miss Erica Diezmos, University of New South Wales	Structure-function analysis of orthosteric and allosteric ligand binding at the adenosine A1 receptor - 237 Mrs Anh TN Nguyen, Monash University	Potential drug interactions with novel oral anticoagulants in elderly hospital inpatients - 245 Ms Heather Forbes, Repatriation General Hospital
14:30 – 14:45	GPR52 – A fine-tuner of striatal signalling in schizophrenia? - 222 Miss Daisy Spark, Monash University	Proteome profiling reveals phosphocofilin1 as a candidate mediator of TGF-β1-induced glucocorticoid resistance - 230 Ms Meina Li, The University of Melbourne	Characterising cellular uptake and distribution of a membrane-anchored neurokinin 1 receptor antagonist - 238 Dr Nicholas Veldhuis, Monash University	The pharmacokinetics and pharmacodynamics of febusostat - 246 Mr Bishoy Kamel, University of New South Wales
14:45 – 15:00	Do human amnion stem cell-derived exosomes improve stroke outcome? - 223 Mr Andrew Ghaly, Monash University	The gut hormone INSL5 activates multiple signalling pathways in the human enterocyte cell line NCI-H716 - 231 Mr Sheng Yu Ang, Monash University	Molecular Determinants of Amylin Receptor Agonism - 239 Ms Rebekah Bower, University of Auckland, New Zealand	Extraction of Metformin During Haemodiafiltration - 247 Miss Felicity Smith, University of New South Wales; St Vincent's Hospital
15:00 – 15:15	Magnesium acetyltaurate provides retinal neuroprotection against NMDA-induced excitotoxicity - 224 Assoc Prof Igor Iezhitsa, Universiti Teknologi MARA, Malaysia	GPR37L1: An orphan G protein-coupled receptor contributing to sex differences in blood pressure regulation - 232 Mr James Coleman, Victor Chang Cardiac Research Institute	Ethanol-oxytocin interactions at homomeric glycine receptors expressed in <i>Xenopus laevis</i> oocytes - 240 Miss Dominique Taylor, The University of Sydney	Cannabinoid interactions with gabapentin in an animal neuropathic pain model - 248 Mr Nicholas Atwal, The University of Sydney
15:15 – 15:30	Deferoxamine can reduce brain injury and enhance functional recovery in a rat model of endothelin-1 induced focal stroke - 225 Dr Nicole Jones, University of New South Wales	Pickpocketing pharmacological neighbours reveals ligands for orphan receptors - 233 Mr Tony Ngo, Victor Chang Cardiac Research Institute	Elucidating the mammary stem cell hierarchy: Insights into breast cancer heterogeneity - 241 Dr Felicity Davis, The University of Queensland	Mechanism-based PK/PD modelling approach to optimise synergistic combinations against multidrug-resistant <i>Pseudomonas aeruginosa</i> (Pa) and in-vivo evaluation in a murine thigh infection model - 249 Mr Rajbharan Yadav, Monash University
15:30 – 15:55	Afternoon tea with exhibitors			
	Clarendon Auditorium Foyer			



16:00 – 18:00	Symposium 5: Inflammation: The key to much pathology	Symposium 6: The Legacy of Henry Krum – making clinical trials fit practice	Symposium 7: Using visualisation in pharmacology education: Right task, right response, better learning	Symposium 8: MPGPCR beyond the bench
	Room: Clarendon Room D	Room: Clarendon Room A	Room: Clarendon Room B	Room: Clarendon Auditorium
	Chairs: Assoc Prof Ross Vlahos and Dr Joanne Hart	Chair: Dr Catherine Lucas	Chair: Dr Lynette Fernandes	Chair: Prof Andrew Tobin
16:00 – 16:30	FPR2 regulates chronic inflammation in Chronic Obstructive Pulmonary Disease (COPD) - 250 Assoc Prof Steven Bozinovski, RMIT University	Specific issues for geriatric patients in clinical trials - 254 Dr Ingrid Hopper, Monash University	Demonstration of knowledge and understanding using visualization - 258 Dr Russell Anderson, Monash University	Therapeutic targeting of cardiac fibrosis - 262 Prof Burns Blaxall, Cincinnati Children's Hospital Medical Center, USA
16:30 – 17:00	Do anti-viral neutrophil responses exacerbate lung inflammation in asthma? - 251 Assoc Prof Brian Oliver, University of Technology Sydney	Clinical trials for the real world - 255 Prof Danny Liew, Monash University	Comparison of visual modalities to enhance student learning - 259 Dr Anna-Marie Babey, University of New England	
17:00 – 17:30	Adenosine receptor biased agonism to treat ischaemic heart disease - 252 Dr Lauren May, Monash University	The Legacy of Henry Krum –making clinical trials fit practice: Where are the children? - 256 Assoc Prof Noel Cranswick, The University of Melbourne	Linking drug-target interaction to response: Filling the gap - 260 Dr Janet Collier, The University of Adelaide	GPCRs beyond the bench: Lessons from the CaSR signalling pathway - 263 Prof Rajesh Thakker, University of Oxford, UK
17:30 – 18:00	Anti-oxidant effects of hydrogen sulphide in the cardiovascular system - 253 Dr Joanne Hart, RMIT University	Fitting the evidence to drug practice - 257 Prof Jennifer Martin, The University of Newcastle	Panel discussion	
18:00 – 19:00	ASCEPT AGM			
	Room: Clarendon Auditorium			
19:00 – 20:00	President's reception (by invitation)			
	Clarendon Room, Level 5			

**MEDICAL BREAKTHROUGHS MAY COME OUT OF THE LAB.
BUT THEY BEGIN IN THE HEART.**

For more than a century, a very special passion has driven the people of MSD. Our goal is to develop medicines, vaccines, and animal health innovations that will improve the lives of millions. Still, we know there is much more to be done. And we're doing it, with a long-standing commitment to research and development. We're just as committed to expanding access to healthcare and working with others who share our passion to create a healthier world. Together, we'll meet that challenge. With all our heart.

 **MSD**
Be well

125
YEARS
SINCE 1891

Copyright © 2016 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All Rights Reserved.

Tuesday 29 November 2016

**Level 2 – Clarendon Auditorium, Clarendon Rooms C, D and E
Level 5 – Clarendon Rooms A and B**

08:00 – 17:00	Registration desk open Clarendon Auditorium Foyer, Melbourne Convention and Exhibition Centre		
08:30 – 09:30	British Toxicological Society keynote address		MPGPCR student oral prize
	Room: Clarendon Auditorium		Room: Clarendon Room A
	Chair: Prof Dom Geraghty		Chair: Dr Lauren May
		08:30 – 08:45	The inner workings of a GPCR: Molecular basis for biased G protein activation and beta-arrestin recruitment - 301 Ms Franziska Heydenreich, Paul Scherrer Institut, Switzerland
		08:45 – 09:00	VCP746, a biased adenosine A1/A2B receptor agonist, promotes divergent cardioprotective signalling from that of NECA, a prototypical adenosine receptor agonist - 302 Miss Jo-Anne Baltos, Monash University
	09:00 – 09:15	Receptor residence time determines bias towards internalisation of the μ opioid receptor - 303 Mr Alexander Gillis, The University of Sydney	
	09:15 – 09:30	Functional consequences of different conformational states of GPCR-β-arrestin complexes - 304 Mr Thomas Cahill, Duke University, USA	
09:30 – 10:25	Morning tea with exhibitors		09:30 – 09:45
	Clarendon Auditorium Foyer ASCEPT Poster presentations: Education; Inflammation/respiratory; Neuro- and Behavioural Pharmacology; Pharmacoepidemiology; Pharmacogenomics; Toxicology; Urogenital and Gastrointestinal		β-Arrestin-biased agonists of the GLP-1 receptor from backbone-modification of GLP-1 - 305 Ms Marlies Hager, University of Wisconsin-Madison, USA
10:30 – 12:30	Symposium 9: Pharmacology of brain neurotransmission	Symposium 10: Role of fibrosis as a driver of, and a treatment target of, impaired cardiovascular and respiratory function	Symposium 11: Evaluation and management of polypharmacy in older adults with multimorbidity and geriatric syndromes
	Room: Clarendon Room A Chair: Prof Andrew Lawrence	Room: Clarendon Room D Chairs: Assoc Prof Rebecca Ritchie and Dr Barb Kemp-Harper	Room: Clarendon Room B Chairs: Prof Sarah Hilmer and Prof Darrell Abernethy
10:30 – 11:00	Is the differential reversal of opioid tolerance by ethanol a consequence of ligand bias? - 306 Prof Graeme Henderson, University of Bristol, UK	Macrophage mineralocorticoid receptor signalling regulates cardiovascular remodelling - 310 Dr Morag Young, Hudson Institute of Medical Research Targeting adenosine receptors for cardiac remodelling - 311 Dr Lauren May, Monash University	What clinical and surrogate outcomes should be used to evaluate medicines in older adults? - 315 Prof Darrell Abernethy, Johns Hopkins University School of Medicine; Food and Drug Administration, USA
11:00 – 11:30	The GABA-B receptor and psychiatric disorders - 307 Dr SJ Enna, University of Kansas Medical Center, USA	Mechanisms downstream of IGF-1R for targeting diabetes-induced cardiac remodeling - 312 Dr Miles De Blasio, Baker IDI Heart & Diabetes Institute Targeting inflammation and fibrosis in early life to protect against life-long respiratory and cardiovascular complications - 313 Dr Jane Bourke, Monash University	Polypharmacy intervention trials - 316 Prof Petra Thuermann, University Witten; HELIOS University Hospital Wuppertal, Germany
11:30 – 12:00	Pharmacology of chaperones in the CNS: Re-emergence of sigma-1 for neuropsychiatric and neurological disorders - 308 Dr James Barrett, Drexel University College of Medicine, USA	Targeting epigenetic mechanisms to limit pulmonary fibrosis in COPD - 314 Prof Philip Hansbro, The University of Newcastle; Hunter Medical Research Institute Panel discussion	Drugomics to understand polypharmacy - 317 Prof David Le Couteur, The University of Sydney; Concord Hospital
12:00 – 12:30	Addiction and the brain: The role of the immune system - 309 Prof Mark Hutchinson, The University of Adelaide		Implementation of drug burden index as a clinical risk assessment tool to guide management of polypharmacy - 318 Prof Sarah Hilmer, Royal North Shore Hospital; The University of Sydney
			Exploiting GPCR bias at formyl peptide receptors to protect against myocardial injury - 319 Assoc Prof Rebecca Ritchie, Baker IDI Heart & Diabetes Institute
			Type I cholecystokinin receptors in metabolic disease. Target of endogenous and therapeutic allosteric modulation - 320 Prof Laurence Miller, Mayo Clinic, USA
			Identification of positive allosteric modulators of the glucagon-like peptide-1 receptor - 321 Dr Francis Willard, Eli Lilly and Company, USA
			Role of cyclic AMP in BRL37344 and isoprenaline mediated glucose uptake by β2-adrenoceptors - 322 Dr Masaaki Sato, Monash University
			Engineering ultra-stable α1-adrenoceptor subtypes allows the interrogation of ligand selectivity and fragment screening using ligand-observed NMR - 323 Dr Daniel Scott, The Florey Institute of Neuroscience and Mental Health

Monash Biomedicine Discovery Institute

Enhancing lives through *discovery*

- We have discovery programs in:**
- Cancer
 - Cardiovascular Disease
 - Development and Stem Cells
 - Metabolic Disease and Obesity
 - Neuroscience
- Partnering with industry to deliver:**
- Solutions to unmet clinical needs
 - A pipeline of translatable discoveries
 - Innovative therapeutics
 - Technologies for research and diagnosis

Research Opportunities in the Department of Pharmacology
Scientists within the Department of Pharmacology, all of whom are members of the BDI at the Clayton Campus, offer a highly collaborative environment for early career and established researchers.

More information can be obtained by contacting Head of Department, Professor Robert Widdop.
Email: robert.widdop@monash.edu

monash.edu/discovery-institute

Department of Pharmacology and Therapeutics,
School of Biomedical Sciences

RESEARCH AND COLLABORATION OPPORTUNITIES AT AUSTRALIA'S LEADING UNIVERSITY

Exciting research and collaboration opportunities with industry engagement in an innovative and inclusive environment for both early career and established researchers. Current projects include:

Lung Health Research Centre

A collaboration with the Royal Melbourne Hospital fostering translational research excellence that closely aligns with patient needs to improve their lung health.

The Therapeutic Technologies Research Initiative (TTRI)

TTRI supports the development of new applications of organ-on-a-chip technology to transform drug-screening processes using principles embedded in the inter-discipline, mechanopharmacology.


Australian Venom Research Unit (AVRU)

An international networked group researching national and regional venomous injury problems and providing up to date information to health networks, industry, media and the community.

BioCurate Pty Ltd

A joint venture with Monash University to realise the full potential of Australia's innovative opportunities to develop new medicines.

biomedsciences.unimelb.edu.au


Providing leadership for research and teaching in Biomedical Sciences

One of Australia's leading Biomedical Sciences Schools with more than 200 Honours and Postgraduate students studying in Pharmacology, Physiology, Neuroscience, Developmental Biology and Anatomy.

Research Themes:

- Therapeutic Development and Translation
- Cell Signaling and Function
- Brain Development and Function
- Tissue Injury and Repair
- Functional Morphology

For information on:
Student opportunities: www.uq.edu.au/sbms/our-research-students
Staff opportunities: www.uq.edu.au/sbms/programs/all
Or contact The Head of School (Acting):
 Professor Rod Minchin at r.minchin@uq.edu.au

 **School of Biomedical Sciences**

www.uq.edu.au/sbms

CRICOS Provider Number 00025B



ISN - ESN

ISN-ESN BIENNIAL MEETING

PARIS, FRANCE
AUGUST 20-24, 2017



Organized by:



Jointly with:






ISN Secretariat: Kenes International
Rue François-Versailles 7
1207 Geneva, Switzerland
Tel: +41 22 908 0488 | Fax: +41 22 906 9140
www.neurochemistry.org



12:30 – 13:25	Lunch with exhibitors			SIG meeting: Drug Disposition and Response
	Clarendon Auditorium Foyer	Sponsored by  School of Health and Biomedical Sciences		Room: Clarendon Room B
13:30 – 13:45	ASCEPT Poster presentations: Education; Inflammation/respiratory; Neuro- and Behavioural Pharmacology; Pharmacoepidemiology; Pharmacogenomics; Toxicology; Urogenital and Gastrointestinal			SIG meeting: Drug Discovery
				Room: Clarendon Auditorium
13:30 – 15:30	Oral presentations 5: Urogenital and Gastrointestinal	Oral presentations 6: Toxicology and Pharmacogenomics	Oral presentations 7: Pharmacoepidemiology	MPGPCR invited ECR session
	Room: Clarendon Room D	Room: Clarendon Room A	Room: Clarendon Room B	Room: Clarendon Auditorium
	Chairs: Dr Betty Exintaris and Prof Russ Chess-Williams	Chair: Dr Daniel Barratt	Chair: Dr Julia Gilmartin	Chair: Prof Steven Charlton
13:30 – 13:45	Identification of novel irritant sensing mechanisms in the bladder - 324 Miss Ashlee Caldwell, University of Adelaide	A pilot feasibility study to assess CYP2B6*6 genotype frequency and adverse effects to efavirenz in HIV/AIDS patients in Papua New Guinea - 332 Prof Andrew Somogyi, University of Adelaide	Fracture risk with zopiclone: Application of a varying-coefficient cox model to examine influence of age as a risk factor for fractures - 340 Dr Prasad Nishtala, University of Otago, New Zealand	Allosteric targeting of metabotropic glutamate receptor 5: New insights and opportunities - 348 Dr Karen Gregory, Monash University
13:45 – 14:00	Nav1.8 is required for mechanosensation in hypersensitive colonic afferents and nav-induced colonic pain in vivo - 325 Ms Andelain Erickson, University of Adelaide	Relationship between whole blood and intra-graft tacrolimus concentrations in renal transplant recipients - 333 Assoc Prof Benedetta Sallustio, The Queen Elizabeth Hospital	Do medications and prescribing patterns increase the risk of hospitalisations from aged care facilities? A systematic review - 341 Miss Kate Wang, Monash University	Exploring conformational landscapes of muscarinic acetylcholine receptors - 349 Dr David Thal, Monash University
14:00 – 14:15	Pharmacology of the human beta3-adrenoceptor agonist mirabegron at the mouse beta3-adrenoceptor - 326 Dr Dana Hutchinson, Monash University	Statin induced myalgia, is there a genetic link? - 334 Dr Simran Maggo, University of Otago, New Zealand	Investigation of hospital opioid prescribing among opioid naive surgical patients - 342 Mr Luke Kardell, The University of Sydney	From surrogate ligands to phenotype: Exploring the function of orphan GPCR, GPR37L1 - 350 Dr Nicola Smith, Victor Chang Cardiac Research Institute; University of New South Wales
14:15 – 14:30	Evidence for mu and delta opioid receptor coexpression and functional interactions in the mouse colon - 327 Mr Jesse Di Cello, Monash University	A pharmacological exploration of the in vitro neurotoxicity of king cobra (ophiophagus hannah) venom - 335 Mr Tam Huynh, Monash University	“Real world” patients are different to trial participants – application of direct oral anticoagulant clinical trial eligibility criteria to a hospitalised cohort - 343 Ms Laura Fanning, Monash University	The role of central beta-3 adrenergic receptors in the control of metabolism and glucose homeostasis - 351 Dr Stephanie Simonds, Monash University
14:30 – 14:45	The tachykinin NK2 receptor antagonist, ibodutant, displays gender- and agonist-dependence in the human colon - 328 Miss Stelina Drimousis, University of New South Wales	Combining Adverse Outcome Pathways with multitask machine learning to simultaneously improve in silico rodent carcinogenicity prediction performance and enable mechanistic interpretation - 336 Mr Davy Guan, The University of Sydney	N-of-1 trials for assessing the effects of deprescribing medications on short-term clinical outcomes in older adults: A systematic review - 344 Mr Alexander Clough, The University of Sydney	
14:45 – 15:00	Legumain is a novel biomarker and therapeutic target in inflammatory bowel disease - 329 Dr Laura Edgington-Mitchell, Monash University	The changing face of snakebite in Australia: 10 years of the Australian snakebite project (ASP) - 337 Dr Christopher Johnston, University of Newcastle	Polypharmacy and the incidence of falls, fractures and weight loss in residential aged care facilities - 345 Dr Jenni Ilomaki, Monash University	Diverse activation pathways in class A GPCRs converge near the G-protein-coupling region - 352 Dr AJ Venkatakrishnan, Stanford University, USA
15:00 – 15:15	Identification of novel sites of TRPV4 expression in the mouse colon - 330 Mr Pradeep Rajasekhar, Monash University	Utilization of multiple reaction monitoring scan mode for the simultaneous determination of amlodipine and lercanidipine in human plasma - 338 Dr Ahmed Abdalla, University of South Australia	Medication review in Australian residential aged care facilities: A systematic review - 346 Ms Esa Chen, Monash University	Enhancing endogenous opioid signalling in the amygdala through positive allosteric modulation of DOR - 353 Dr Bryony Winters, The University of Sydney
15:15 – 15:30	Biological effects on rat prostatic smooth muscle and chemical fractionation of costus speciosus rhizome - 331 Ms Eunice Su Nguok Ngie, Monash University	Gelofusine ameliorates colistin-induced nephrotoxicity - 339 Miss Shaz Sivanesan, Monash University	Evaluation of the national minimum dataset for neurological conditions in older adults - 347 Ms Sujita Narayan, University of Otago, New Zealand	
15:30 – 15:55	Afternoon tea with exhibitors			
16:00 – 17:00	MPGPCR keynote address			
	Room: Clarendon Auditorium			
	Chair: Prof Patrick Sexton			
	GPCRs and ACRs (Arrestin-coupled receptors): A tale of two transducers - 354 Prof Robert J Lefkowitz, Nobel Laureate, Duke University Medical Center, USA			Sponsored by  
17:00 – 18:00	MPGPCR poster presentations			
	Clarendon Auditorium Foyer			
19:00 – 23:00	Meeting dinner			
	Showtime Events Centre, 61 South Wharf Promenade, South Wharf			

Wednesday 30 November 2016

08:00 – 16:30	Registration desk open			
	Clarendon Auditorium Foyer, Melbourne Convention and Exhibition Centre			
08:30 – 09:30	Keynote presentation			
	Room: Clarendon Auditorium			
	Chair: Prof Dom Geraghty			
	Unravelling the circuitry and chemistry of reward-seeking - 400 Prof Andrew Lawrence, Florey Institute for Neuroscience and Mental Health			
09:30 – 10:25	Morning tea with exhibitors			
	Clarendon Auditorium Foyer	Sponsored by 		09:55am – 10:25 SIG meeting: Neuro- and Behavioural Pharmacology
	MPGPCR poster presentations			Room: Clarendon Auditorium
10:30 – 12:30	Symposium 13: Safe prescribing: now and the future	Symposium 14: IUPHAR and therapeutic targeting	Symposium 15: Ion channel function and dysfunction in the vascular, and gastrointestinal and urogenital tracts	Symposium 16: MPGPCR Molecular neuroscience
		Sponsored by 		Sponsored by 
	Room: Clarendon Room A	Room: Clarendon Room B	Room: Clarendon Room D	Room: Clarendon Auditorium
	Chairs: Prof Sepehr Shakib and Prof Sarah Hilmer	Chairs: Dr SJ Enna and Dr Michael Spedding	Chairs: Dr Paul Bertrand and Assoc Prof Lu Liu	Chair: Dr Michelle Halls
10:30 – 11:00	What I wish I knew: An intern's prescribing journey - 401 Dr Arunima Jain, The Canberra Hospital	IUPHAR: Its organization and mission for world health - 405 Dr SJ Enna, IUPHAR	TRPA1 channels and serotonin release from enterochromaffin cells - 410 Dr Paul Bertrand, RMIT University	Molecular mechanisms of pain control by opioid receptors - 414 Prof Gregory Scherrer, Stanford University, USA
11:00 – 11:30	Prescribing curriculum and competency - 402 Prof Sarah Hilmer, Royal North Shore Hospital; The University of Sydney	IUPHAR: Pharmacological variables and therapeutic targeting - 406 Dr Michael Spedding, IUPHAR	Ion channels and visceral afferents in the gut and bladder - 411 Assoc Prof Stuart Brierley, Flinders University; South Australian Health and Medical Research Institute	Location-dependent signaling of metabotropic glutamate receptor 5, mGlu5 - 415 Prof Karen O'Malley, Washington University School of Medicine, USA
11:30 – 12:00	PSA – is it the solution? - 403 Dr Claire Harrison, Monash University	Synergies and challenges for academic/pharma drug targeting - 407 Dr James Barrett, IUPHAR	Local and regional regulation of endothelial function in diabetes - 412 Dr Marianne Tare, Monash University	Orphans and veterans: GPCR-mediated regulation of striatal function - 416 Dr Chris Langmead, Monash University
12:00 – 12:30	ePrescribing – the devil is in the detail - 404 Assoc Prof Matt Doogue, The University of Otago, New Zealand	The specific challenges in India/Africa/China - 408 Dr Bhagirath Patel, IUPHAR; Dr Guanhua Du, Chinese Pharmacological Society	TRPV3 control of uterine blood vessels - 413 Dr Tim Murphy, University of New South Wales	Controlling efficacy at G protein coupled receptors; ligand-dependent modulation of G protein conformation and activity at the calcitonin receptor - 417 Dr Sebastian Furness, Monash University
	Panel Discussion	Critical role of clinical pharmacology in therapeutic targeting - 409 Dr Darrell Abernethy, Dr David Webb, IUPHAR		Cooperativity as the molecular basis of allosteric modulator receptor subtype-selectivity at muscarinic receptors - 418 Dr Celine Valant, Monash University
12:30 – 13:25	Lunch with exhibitors			SIG meeting: Clinical Pharmacology
	Clarendon Auditorium Foyer			Room: Clarendon Room A
	MPGPCR poster presentations and ASCEPT student poster finalists presentation			12:55-12:25 SIG meeting: Cardiovascular
				Room: Clarendon Room B

13:30 – 15:30	Oral presentations 8: Clinical Pharmacology Trainees and Drug Disposition and Response	Oral presentations 9: Cardiovascular	Oral presentations 10: Education	Symposium 17: MPGPCR Novel insights into structure & signaling
	Room: Clarendon Room A	Room: Clarendon Room B	Room: Clarendon Room D	Room: Clarendon Auditorium
	Chair: Assoc Prof Matt Doogue	Chairs: Dr Jason Peart and Dr Brad Broughton	Chair: Assoc Prof Shane Bullock	Chair: Dr Katie Leach
13:30 – 13:45	Diagnosing and recording adverse drug reactions in general medical patients, a cross-sectional study - 419 Dr Niall Hamilton, Canterbury District Health Board, New Zealand	Cardiac-selective bone morphogenetic protein 7 (BMP7) gene therapy to target cardiac fibrosis in a mouse model of diabetic cardiomyopathy - 427 Dr Mitchel Tate, Baker IDI Heart & Diabetes Institute	Peer feedback and scaffolding student learning: Developing an authentic assessment - 435 Dr Angela Finch, University of New South Wales	Allostery in GPCR signalling - 439 Dr Dmitry Veprintsev, Paul Scherrer Institute, Switzerland
13:45 – 14:00	Effectiveness of interventions to deprescribe inappropriate proton pump inhibitors in older adults: A systematic review - 420 Dr Tom Wilsdon, Flinders Medical Centre	Clinical experience with pharmacological conditioning of donor hearts with glyceryl trinitrate (GTN) and erythropoietin (EPO) after declaration of circulatory death (DCD) - 428 Dr Mark Hicks, St Vincent's Hospital	Evaluating student perceptions of current laboratory report feedback - 436 Dr Klaudia Budzyn, Monash University	
14:00 – 14:15	The uptake of TPMT pharmacogenomic testing across specialty units at a tertiary hospital - 421 Dr David Liew, Austin Health	Interleukin-18 is crucial for the development of renal inflammation and elevated blood pressure in a mouse model of hypertension - 429 Ms Jordyn Thomas, Monash University	Surviving bioscience and pharmacology; an eBook for accelerated nursing students - 437 Dr Sheila Duggrell, Queensland University of Technology	
14:15 – 14:30	Restarting psychoactive medications post intentional overdose: A move towards a consensus - 422 Dr Emma Tay, St Vincent's Hospital	Functional and inflammatory effects of thrombotic cortical stroke in males and females - 430 Miss Catherine Nguyen, Monash University	Developing student awareness of potential career options in the pharmaceutical industry - 438 Dr Barbara Kemp-Harper, Monash University	Novel insights into class B GPCR activation and signaling - 440 Dr Denise Wootten, Monash University
14:30 – 14:45	Meropenem stability in 24 hour continuous infusion; a simulation study - 423 Dr Katherine Langan, Monash University; The Alfred Hospital	Shear stress mediates cell surface expression and interaction of TRPV4 with other mechanoreceptors - 431 Dr Sara Baratchi, RMIT University	Structural mechanism of ligand activation in class C GPCRs - 441 Dr Qing Fan, Columbia University, USA	
14:45 – 15:00	Challenges of an electronic medication management system. The evolving role of a clinical pharmacologist in interpreting current evidence and implementing this into an eMM system - 424 Dr Christopher Morris, Princess Alexandra Hospital	Influence of ACE inhibitors on frailty and cardiac function in middle-aged female C57BL/6 mice - 432 Dr Alice Kane, Dalhousie University, Canada		
15:00 – 15:15	Participation of clinical pharmacology trainees in TGL expert groups - 425 Prof Robert Moulds, Therapeutic Guidelines	CCL18 as a mediator of the pro-fibrotic actions of M2 macrophages in the vessel wall during hypertension - 433 Miss Mingyu Zhu, Monash University		
15:15 – 15:30	Substantial impact of altered PK in critically ill (ICU) patients on the antibacterial effects of meropenem evaluated via mechanism-based modelling (MBM) and the hollow-fibre infection model (HFIM) - 426 Dr Cornelia Landersdorfer, Monash University	Plasma cell differentiation is not essential for the pro-hypertensive actions of B cells - 434 Miss Seyuri Moodley, Monash University	Afternoon tea	
15:30 – 16:00	ASCEPT prize giving Room: Clarendon Auditorium Chair: Prof Dom Geraghty			
16:00 – 17:00	Symposium 18: MPGPCR structural biology Room: Clarendon Auditorium Chair: Dr Denise Wootten			
16:00 – 16:30	Chemokines and their receptors: Structural insights into binding, activation, specificity, and antagonism - 442 Dr Irina Kufareva, University of California, San Diego, USA			
16:30 – 17:00	Structural studies of purinergic receptors P2Y1R and P2Y12R - 443 Prof Beili Wu, Shanghai Institute of Materia Medica, China			
17:00 – 18:00	Closing keynote address Room: Clarendon Auditorium Chair: Dr Chris Langmead Structural insights into the dynamic process of G protein coupled receptor signaling - 444 Prof Brian Kobilka, Nobel Laureate, Stanford University, USA			
18:00 – 18:15	MPGPCR prize giving and meeting close Room: Clarendon Auditorium Chair: Dr Chris Langmead			

Sponsored by



MONASH University
Institute of Pharmaceutical Sciences

Thank you to our sponsors

Principal sponsor



Major sponsor



Key sponsors



Sponsors



Supporters



Exhibitors



**Ranked #4 in world for Pharmacy & Pharmacology
#1 in Asia-Pacific**



MONASH University
Institute of Pharmaceutical Sciences



Enhanced Doctoral Program in Pharmacy & Pharmaceutical Sciences: Drug Discovery Biology

KEY FEATURES:

- 4-year degree
- 3x 6-week rotations in different labs (year 1)
- Advanced Course in Drug Discovery & Development (in year 1)
- No overlap between coursework & rotations
- Independent academic mentor
- Independent peer mentor
- Theme researchers publish in leading journals, e.g. Nature, Cell, Nature Chem Biol, Nature Comm, Cell Res, PNAS

Enquiries:

Pharm-ddb-enquiries@monash.edu

For further information:

<https://www.monash.edu/pharm/research/areas/drug-discovery/postgrad-study>

